No Data
No Data
Ionis Pharmaceuticals Says Transthyretin-Mediated Amyloidosis Treatment Gets Approval in Europe
Ionis and AstraZeneca Win EU Approval for WAINZUA, a Self-Injectable Treatment for Rare Nerve Disease
Express News | Wainzua (Eplontersen) Approved in the EU for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults With Stage 1 or Stage 2 Polyneuropathy
Ionis to Present at Upcoming Investor Conferences
Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $38
Stifel Nicolaus Remains a Hold on Ionis Pharmaceuticals (IONS)